Lundbeck to Acquire Prexton Therapeutics

21.03.2018 - Danish drugmaker Lundbeck has announced plans to buy Swiss drug developer Prexton Therapeutics in a deal worth up to €905 million. The deal would give Lundbeck global rights to...